… classes, in particular an inhaled muscarinic antagonist with an inhaled β 2 -agonist, seems a
… More recently, long-acting β 2 -agonists (LABAs) and muscarinic antagonists (LAMAs) have …

… The aim of this study was to examine the clinical efficacy and safety of long-acting muscarinic
antagonist (LAMA) and long-acting beta2-agonist (LABA) in patients with stable COPD. We …

ABSTRACT Objective: To determine whether long-acting muscarinic antagonists (LAMAs)
provide superior therapeutic effects over long-acting β2 agonists (LABAs) for preventing …

… Fixed‐dose combinations (FDCs) of a long‐acting beta 2 ‐agonist (LABA) plus a long‐acting
muscarinic antagonist (LAMA) delivered via a single inhaler are approved by regulatory …

Background: A number of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)
fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic …

… LAMAs are used either alone or associated with long-acting β 2 -agonists, eventually in
fixed dose combinations. Long-acting β 2 -agonist/LAMA combinations assure additional …

… , particularly muscarinic antagonists and β 2 agonists, are … Dual-pharmacology muscarinic
antagonist– β 2 agonist (… of COPD by combining muscarinic antagonism and β 2 agonism in a …

… All muscarinic antagonists currently used as bronchodilating … of postsynaptic β 2 -adrenoceptors
and presynaptic β 2 -… of agonist-induced signalling via specific muscarinic receptor …

Background Maintenance treatment with long‐acting beta 2‐agonists and inhaled corticosteroids
(LABA/ICS) can relieve asthma symptoms and reduce the frequency of exacerbations, …

… However, in these studies, the muscarinic antagonist (MA) and BAs were dosed separately,
… molecule with dual pharmacology (muscarinic antagonist and β 2 -AR agonist, MABA) that …